Literature DB >> 14747958

Iodine-131 treatment and chromosomal damage: in vivo dose-effect relationship.

Taner Erselcan1, Selma Sungu, Semra Ozdemir, Bulent Turgut, Derya Dogan, Ozturk Ozdemir.   

Abstract

Although it is well known that radiation induces chromosomal aberrations, there is a lack of information on the in vivo dose-effect relationship in patients receiving iodine-131 treatment, and the results of previous studies are controversial. In this study, the sister chromatid exchange (SCE) method was employed to investigate acute and late chromosomal damage (CD) in the peripheral lymphocytes of 15 patients who received various doses of (131)I (259-3,700 MBq), either for thyrotoxicosis (TTX) or for ablation treatment in differentiated thyroid cancer (DTC). The SCE frequencies in cultured peripheral lymphocytes were determined before treatment (to assess basal SCE frequencies), on the 3rd day (to assess acute SCE frequencies) and 6 months later (to assess late SCE frequencies). The basal, acute and late SCE frequencies (mean+/-SD) were 3.19+/-0.93, 10.83+/-1.72 and 5.75+/-2.06, respectively, in the whole group, and these values differed significantly from each other ( P<0.001). In order to perform a quantitative evaluation of the present data and a comparative analysis with the results of previous studies reported in the literature, we defined acute and late effects using a "damage ratio" (DR) and a "recovery ratio" (RR), based on the basal, acute and late data for individual patients. No statistically significant difference was found in the DR between DTC and TTX patients (76.4%+/-11.5% vs 67.6%+/-9.0%), while the mean RR was higher in TTX patients than in the DTC group (75.2%+/-24.4% vs 36.8%+/-13.7%). The DR on the 3rd day was not related to the administered (131)I dose in the whole group, but a negative correlation was found between the (131)I dose and the RR at the 6th month (r=-0.60, P=0.04). The best fit for this relationship was obtained by a linear-quadratic model, as y=104.89x-28.4x(2)+38.1 ( R(2)=0.51, P=0.04). On the other hand, comparative analysis with the results of previous studies with comparable sampling times revealed that the best fit for the relationships between the administered dose of (131)I and DR and RR were obtained with a linear-quadratic model (Y=alpha D+beta D(2)) rather than a linear one. However, there was an interesting difference in comparison with in vitro studies, in that we found the coefficient beta to have a negative value, suggesting the disappearance of damaged lymphocytes from the peripheral circulation in a dose-dependent manner following (131)I treatment. Further studies are therefore needed to clarify the effect of the negative beta value on the biological dosimetry approach in continuous internal low LET radiation, as in the case of (131)I treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14747958     DOI: 10.1007/s00259-003-1427-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  40 in total

1.  Genotoxic effects of radiotherapy and chemotherapy on circulating lymphocytes in patients with Hodgkin's disease.

Authors:  C Bilban-Jakopin; M Bilban
Journal:  Mutat Res       Date:  2001-10-18       Impact factor: 2.433

2.  Formation of micronuclei and of clastogenic factor(s) in patients receiving therapeutic doses of iodine-131.

Authors:  Michela Ballardin; Federica Gemignani; Lisa Bodei; Giuliano Mariani; Marco Ferdeghini; Anna Maria Rossi; Lucia Migliore; Roberto Barale
Journal:  Mutat Res       Date:  2002-02-15       Impact factor: 2.433

3.  Genetic risk assessment after iodine-131 exposure: an opportunity and obligation for nuclear medicine.

Authors:  M E Dottorini
Journal:  J Nucl Med       Date:  1996-04       Impact factor: 10.057

4.  Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin.

Authors:  B de Keizer; H P Koppeschaar; P M Zelissen; C J Lips; P P van Rijk; A van Dijk; J M de Klerk
Journal:  Eur J Nucl Med       Date:  2001-02

Review 5.  Radiosensitivity of tumor cells. Oncogenes and apoptosis.

Authors:  L T Peltenburg
Journal:  Q J Nucl Med       Date:  2000-12

6.  Application of the single cell gel electrophoresis (SCGE) assay to the detection of DNA damage induced by 131I treatment in hyperthyroidism patients.

Authors:  S Gutiérrez; E Carbonell; P Galofré; A Creus; R Marcos
Journal:  Mutagenesis       Date:  1998-01       Impact factor: 3.000

7.  Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans.

Authors:  Myriam Monsieurs; Boudewijn Brans; Klaus Bacher; Rudi Dierckx; Hubert Thierens
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-10-02       Impact factor: 9.236

8.  Estimation of risk based on biological dosimetry for patients treated with radioiodine.

Authors:  M A Monsieurs; H M Thierens; C V van de Wiele; A M Vral; I A Meirlaen; H A de Winter; C J de Sadeleer; L I de Ridder; J M Kaufman; R A Dierckx
Journal:  Nucl Med Commun       Date:  1999-10       Impact factor: 1.690

9.  Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis.

Authors:  T Mizuno; S Kyoizumi; T Suzuki; K S Iwamoto; T Seyama
Journal:  Oncogene       Date:  1997-09-18       Impact factor: 9.867

10.  Sequential biological dosimetry after a single treatment with iodine-131 for differentiated thyroid carcinoma.

Authors:  R M'Kacher; J D Légal; M Schlumberger; B Aubert; N Beron-Gaillard; A Gaussen; C Parmentier
Journal:  J Nucl Med       Date:  1997-03       Impact factor: 10.057

View more
  11 in total

1.  Cytogenetic and dosimetric effects of (131)I in patients with differentiated thyroid carcinoma: comparison between stimulation with rhTSH and thyroid hormone withdrawal treatments.

Authors:  Márcia Augusta da Silva; Flávia Gomes Silva Valgôde; Júlia Armiliato Gonzalez; Hélio Yoriyaz; Maria Inês Calil Cury Guimarães; Maria Teresa Carvalho Pinto Ribela; Carlos Alberto Buchpiguel; Paolo Bartolini; Kayo Okazaki
Journal:  Radiat Environ Biophys       Date:  2016-03-24       Impact factor: 1.925

2.  Systemic oxidative stress to nucleic acids is unaltered following radioiodine therapy of patients with benign nodular goiter.

Authors:  Steen J Bonnema; Elisabeth S Stovgaard; Søren Fast; Kasper Broedbaek; Jon T Andersen; Allan Weimann; Peter Grupe; Laszlo Hegedüs; Henrik E Poulsen
Journal:  Eur Thyroid J       Date:  2015-02-11

3.  Predictive factors of cytotoxic damage in radioactive iodine treatment of differentiated thyroid cancer patients.

Authors:  Satoru Monzen; Yasushi Mariya; Andrzej Wojcik; Chika Kawamura; Ayumi Nakamura; Mitsuru Chiba; Masahiro Hosoda; Yoshihiro Takai
Journal:  Mol Clin Oncol       Date:  2015-01-27

4.  Evaluation of the radioprotective effect of turmeric extract and vitamin E in mice exposed to therapeutic dose of radioiodine.

Authors:  Uma S Bhartiya; Yogita S Raut; Lebana J Joseph; Rohini W Hawaldar; Badanidiyoor S Rao
Journal:  Indian J Clin Biochem       Date:  2008-12-20

5.  Evaluation of the cytogenetic effects of (131)I preceded by recombinant human thyrotropin (rhTSH) in peripheral lymphocytes of Wistar rats.

Authors:  Márcia Augusta da Silva; Maria Inês Calil Cury Guimarães; Hélio Yoriyaz; Maria Teresa Carvalho Pinto Ribela; Carlos Alberto Buchpiguel; Paolo Bartolini; Kayo Okazaki
Journal:  Radiat Environ Biophys       Date:  2008-08-19       Impact factor: 1.925

6.  Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine.

Authors:  R J Molenaar; C Pleyer; T Radivoyevitch; S Sidana; A Godley; A S Advani; A T Gerds; H E Carraway; M Kalaycio; A Nazha; D J Adelstein; C Nasr; D Angelini; J P Maciejewski; N Majhail; M A Sekeres; S Mukherjee
Journal:  Leukemia       Date:  2017-11-06       Impact factor: 11.528

7.  No evidence of chromosome damage in children and adolescents with differentiated thyroid carcinoma after receiving 131I radiometabolic therapy, as evaluated by micronucleus assay and microarray analysis.

Authors:  Giovanni Federico; Giuseppe Boni; Barbara Fabiani; Lisa Fiore; Patrizia Lazzeri; Francesco Massart; Claudio Traino; Carmela Verola; Giuseppe Saggese; Giuliano Mariani; Roberto Scarpato
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-22       Impact factor: 9.236

8.  Micronucleus frequencies in groups receiving external or internal radiation.

Authors:  Ayşegül Özdal; Taner Erselcan; Öztürk Özdemir; Güler Silov; Zeynep Erdoğan; Özgül Turhal
Journal:  Indian J Nucl Med       Date:  2016 Jul-Sep

9.  Biological Response of Positron Emission Tomography Scan Exposure and Adaptive Response in Humans.

Authors:  Kara Schnarr; Timothy F Carter; Daniel Gillis; Colin Webber; Jennifer A Lemon; Ian Dayes; Joanna A Dolling; Karen Gulenchyn; Douglas R Boreham
Journal:  Dose Response       Date:  2015-11-19       Impact factor: 2.658

10.  Protective Effect of Alpha-Lipoic Acid on Salivary Dysfunction in a Mouse Model of Radioiodine Therapy-Induced Sialoadenitis.

Authors:  Jung Hwa Jung; Jin Hyun Kim; Myeong Hee Jung; Seung Won Kim; Bae Kwon Jeong; Seung Hoon Woo
Journal:  Int J Mol Sci       Date:  2020-06-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.